menu

CME: Promising Bifunctional Agents in Immuno-Oncology: A Roundtable Discussion with the Experts

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Promising Bifunctional Agents in Immuno-Oncology: A Roundtable Discussion with the Experts

Promising Bifunctional Agents in Immuno-Oncology: A Roundtable Discussion with the Experts
RestartResume
Join immuno-oncology experts as they discuss the emerging role of TGF-beta and the potential opportunities of M7824 to target cancer.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The presence of transforming growth factor-beta (TGF-β) in the tumor microenvironment plays a main role in limiting the clinical efficacy of anti-PD-1/PD-L1 checkpoint inhibitors. Not only does TGF-β suppress the normal anti-tumor action of natural killer cells and T cells, but it is also involved in many processes of cancer progression and metastasis, such as fibroid cap formation, epithelial-to-mesenchymal transition, and angiogenesis.

    This panel will discuss the latest findings in the role of TGF-β in tumor formation and progression, as well as treatment advances that target PDL1 and TGF-β pathways simultaneously.  

    For more episodes in this series, visit ReachMD.com/IO.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    James L. Gulley, MD, PhD, FACP
    Chief, Genitourinary Malignancies Branch
    Head, Immunotherapy Group, GMB
    Director, Medical Oncology Service
    Center for Cancer Research, NCI, NIH
    Bethesda, MD 

    Dr. Gulley has nothing to disclose. 

    Faculty: 
    Scott Kopetz, MD, PhD, FACP
    Associate Professor
    Department of Gastrointestinal Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, TX

    Dr. Kopetz receives consulting fees from Amal Therapeutics, Biocartics, Merck KGA, Navire Pharma, Roche/Genentech, and Symphogen.

    Luis Paz-Ares, MD, PhD
    Head, Lung Cancer Unit
    National Oncology Research Center
    Madrid, Spain

    Dr. Paz-Ares receives honoraria for medical advisory from Amgen Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Clovis Oncology, Eli Lilly and Company, MSD, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Roche Holding AG.

    Reviewers/Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • John Pirovitz has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the rationale for using bispecific, bifunctional fusion protein molecules as a treatment modality for patients with a range of cancer types.
    • Summarize the critical relationships between PD-L1 and TGF-β in regulating tumor growth and metastasis, forming the rational for bispecific, bifunctional fusion protein molecules that contain “biologic traps,” as one part of immuno-oncologic efforts to harness the immune system when treating a range of cancer types.
    • Discuss data from early phase clinical data providing proof of concept for M7824 as a treatment modality for patients with cancer.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, hematologists, and medical oncologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider

    TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent medical education grant provided by Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of TOPEC Global you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients with cancer. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”.  

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.